Enterobacteriaceae resistant to third generation cephalosporins upon hospital admission: Risk factors and clinical outcomes

Brazilian Journal of Infectious Diseases

Volumn 19, Issue 3, 2015, Pages 239-245

  Oliveira, Mirian Cristina ^a   Oliveira, Clara Rodrigues Alves ^a   Gonçalves, Karine Valéria ^a   Santos, Marciléa Silva ^a   Tardelli, Amanda Cristina Silva ^a   Nobre, Vandack Alencar ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antibiotic resistance; Enterobacteriaceae; Risk factors; Third generation cephalosporins

Indexed keywords

CEPHALOSPORIN DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; ENTEROBACTERIACEAE; FEMALE; HEALTH IMPACT ASSESSMENT; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; CLASSIFICATION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; MICROBIOLOGY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84930081296     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2015.01.006     Document Type: Article

References (33)

1. Paterson D. Resistance in gram negative bacteria: Enterobacteriaceae. Am J Infect Control 2006, 34:S21-S28.
2. Coque T., Baquero F., Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008, 13:1-11.
3. Bush K. Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 2010, 14:224-231.
4. Asensio A., Alvarez-Espejo T., Fernandez-Crehuet J.A.R., et al. Trends in yearly prevalence of third-generation cephalosporin and fluoroquinolone resistant Enterobacteriaceae infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010. Euro Surveill 2011, 16:19983.
5. Pitout J.D.D., Laupland K.B. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Infection 2008, 8:159-166.
6. Hawkey P.M., Jones A.M. The changing epidemiology of resistance. J Antimicrob Chemother 2009, 64:i3-i10.
7. Rodriguez-Banõ J., Picón E., Gijó P., Hernández J., Ruíz M., Penã C. Community-onset bacteremia due to extended-spectrum β-lactamase - producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010, 50:40-48.
8. Saely S., Kaye K., Fairfax M., Chopra T. Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum β-lactamase producing Klebsiella pneumoniae. Am J Infect Control 2011, 39:390-395.
9. Doernberg S.B., Winston L.G. Risk factors for acquisition of extended-spectrum β-lactamasee producing Escherichia coli in an urban county hospital. Am J Infect Control 2012, 40:123-127.
10. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically III patients. Chest 1999, 115:462-474.
11. Lautenbach E., Patel J., Bilker W., Edelstein P., Fishman O. Extended-spectrum β-lactamase - producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001, 32:1162-1171.
12. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 21th informational suplement. Aprpoved standart M100-S21 2011, CLSI, Wayne, PA.
13. Bradford P.A. Extended-spectrum β-lactamases in the 21st century:characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001, 14:933-951.
14. Villegas M., Blanco M., Sifuentes-Osornio J., Rossi F. Increasing prevalence of extended-spectrum-beta lactamase among Gram-negative bacilli in Latin America - 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Braz J Infect Dis 2011, 15:34-39.
15. Hawser S., Bouchillon S., Hoban D., Badal R. Emergence of high levels of extended-spectrum-β-lactamase-producing Gram-Negative Bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007. Antimicrob Agents Chemother 2009, 53:3280-3284.
16. Gniadkowski M. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001, 7:597-608.
17. Pitout J., Nordmann P., Laupland K., Poirel L. Emergence of Enterobacteriaceae producing extended spectrum β-lactamase (ESBLs) in the community. J Antimicrob Chemother 2005, 56:52-59.
18. Nogueira K., Higuti I., Nascimento A., Terasawa L. Occurrence of extended-spectrum β-lactamases in Enterobacteriaceae Isolated from hospitalized patients in Curitiba, southern Brazil. Braz J Infect Dis 2006, 10:390-395.
19. Superti S., Augusti G., Zavascki A.P. Risk factors for and mortality of extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Rev Inst Med Trop Sao Paulo 2009, 51:211-216.
20. Lenhard-Vidal A., Cardoso R., Pádua R., Siqueira V. High prevalence rate of extended-spectrum beta-lactamases (ESBL)among Enterobacteriaceae in a small Brazilian public hospital. Braz J Pharm Sci 2011, 47:701-707.
21. Santos D., Pimenta F., Alves R., Montalvão D., Santos D., Carmo Filho J.R. Extended-spectrum β-lactamases producing Klebsiella pneumoniae isolated in two hospitals in Goiânia/Brazil: detection, prevalence, antimicrobial susceptibility and molecular typing. Braz J Microbiol 2008, 39:608-612.
22. Minarini L., Poirela L., Trevisani N., Darini A., Nordmann P. Prevalence of community-occurring extended spectrum β-lactamase-producing Enterobacteriaceae in Brazil. Curr Microbiol 2007, 54:335-341.
23. Wollheim C., Guerra I., Conte V., et al. Nosocomial and community infections due to class A extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in southern Brazil. Braz J Infect Dis 2011, 15:138-143.
24. Ben-Ami R., Rodriguez-Banõ J., Pitout J., et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009, 49:682-690.
25. Lee J., Kang C., Joo E.J., et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Microb Drug Resist 2010, 17:267-273.
26. De Rosa F.G., Pagani N., Fossati L., et al. The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection 2011, 39:555-561.
27. Kang C.I., Wi Y.M., Lee M.Y., et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol 2010, 50:312-317.
28. Rodriguez-Banõ J., Alcala J., Cisneros J., Grill F. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Ann Intern Med 2008, 168:1897-1902.
29. Calbo E., Romaní V., Xercavins M., et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases. J Antimicrob Chemother 2006, 57:780-783.
30. Behar P., Teixeira P., Fachel J., Kalil A. The effect of control group selection in the analysis of risk factors for extended spectrum β-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. J Hosp Infect 2008, 68:123-129.
31. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended espectrum β-lactamase producion in Enterobacteriacea bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60:913-920.
32. Tumbarello M., Trecarichi E.M., Bassetti M., et al. Identifying patients harboring extended-spectrum-β-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 2011, 55:3485-3490.
33. Mauldin P., Salgado C., Hansen I., Durup D., Bosso J. Attributable hospital cost and length of stay associated with health care-associated infections caused byantibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 2010, 54:109-115.